Novartis CMO John Tsai

No­var­tis suc­ceeds where Alex­ion failed, com­ing up with a win for a prized as­set in a rare kid­ney dis­or­der

Three months af­ter Alex­ion stum­bled, No­var­tis de­clared an­oth­er Phase II suc­cess for a drug it hopes can carve out sig­nif­i­cant new in­di­ca­tions and po­ten­tial­ly com­pete with Soliris.

No­var­tis said to­day that ip­ta­co­pan, al­so known as LNP023, suc­cess­ful­ly cut pro­tein­uria — el­e­vat­ed pro­tein lev­els in urine, an in­di­ca­tor of kid­ney in­flam­ma­tion — in half across 12 pa­tients with the rare kid­ney dis­ease C3G (P=0.0005). That’s the same dis­ease where, in Ju­ly, one of the two big drugs Alex­ion picked up in their $930 mil­lion Achillion buy­out flopped.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.